Next Steps for Immunotherapy in Glioblastoma

Toni Q. Cao*, Derek A. Wainwright, Catalina Lee-Chang, Jason Miska, Adam M. Sonabend, Amy B. Heimberger, Rimas V. Lukas

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.

Original languageEnglish (US)
Article number4023
Issue number16
StatePublished - Aug 2022


  • glioblastoma
  • immune system
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Next Steps for Immunotherapy in Glioblastoma'. Together they form a unique fingerprint.

Cite this